Daily Reports
34 reports available
August 11, 2026
Verified research updates for families.
August 10, 2026
August 9, 2026
August 8, 2026
August 7, 2026
August 6, 2026
June 25, 2026
A recruiting Phase 2 trial is testing D-serine against placebo in 100 people with Parkinson's, looking at whether it can change disease severity scores over tim...
June 21, 2026
A new phase 1 study is testing whether DopaCell, a lab-grown dopamine nerve-cell precursor, can be transplanted into both sides of the striatum in people with m...
June 20, 2026
A small randomized crossover feasibility trial tested adaptive deep brain stimulation, or DBS that adjusts stimulation to a person’s walking rhythm, in five peo...
June 19, 2026
DAPA-PD (NCT07157735) is recruiting 36 people with early Parkinson’s disease for a Phase 2, randomized, placebo-controlled trial of dapansutrile, an oral NLRP3 ...
June 18, 2026
A blinded randomized crossover trial tested gait-synchronized adaptive deep brain stimulation in five people with Parkinson's disease. The system adjusted stimu...
June 17, 2026
In the phase 3 TEMPO-1 trial, adults with early Parkinson's disease who took tavapadon, an oral once-daily D1/D5 agonist, had significantly better motor scores ...
June 12, 2026
The PASADENA trial's open-label extension continues to show that prasinezumab (RO7046015/PRX002) — a monoclonal antibody targeting aggregated α-synuclein — prod...
June 10, 2026
GEN Pharmaceuticals announced June 8, 2026 that the first patient has been dosed in a Phase II proof-of-concept trial for SUL-238, a novel compound targeting mi...
June 8, 2026
The landscape of Parkinson's clinical trials in 2026 is defined by precision medicine approaches. Gene therapy trials targeting GBA1 mutations — which account f...
June 2, 2026
More than 400 Parkinson's disease clinical trials are actively recruiting patients in 2026 — a decisive turning point for a field long stuck in symptom manageme...
May 31, 2026
A new Phase 2 study (NCT07174310) is evaluating prasinezumab against placebo in participants with early-stage Parkinson's disease who are already on stable levo...
May 30, 2026
A Phase 1/2a clinical trial is evaluating ANPD001 — an experimental cell therapy that involves transplanting dopamine-producing cells into the brains of people ...
May 29, 2026
Researchers at the Perelman School of Medicine at the University of Pennsylvania have identified a brain immune protein that may play a major role in the progre...
May 24, 2026
A comprehensive database tracks 19 actively recruiting clinical trials for Parkinson's disease as of May 2026. Studies cover gene therapy, neuroprotective agent...
May 21, 2026
The Parkinson's Progression Markers Initiative (PPMI) is recruiting volunteers with and without Parkinson's disease age 18 and older in the U.S. This landmark s...
April 9, 2026
A Phase 2a multicenter study is evaluating TB006, an investigational antibody therapy, in participants with Parkinson's disease. The trial is currently recruiti...
April 8, 2026
Gene Therapy for Advanced Parkinson's
April 7, 2026
Hearing Loss May Signal Early Parkinson's
April 6, 2026
The first AI-designed Parkinson's trial is personalizing adaptive deep brain stimulation (aDBS) by using machine learning to predict which patients respond best...
April 5, 2026
A Phase 1/2 study at UCSF is testing AAV2-GDNF — a gene therapy that delivers the GDNF protein directly into the brain via a surgical procedure. The goal is to ...
April 4, 2026
A Phase 2 study is testing AAV2-GDNF — a gene therapy delivered directly into the brain — to see if it can slow or improve motor symptoms in people with moderat...
April 3, 2026
Tavapadon is a once-daily pill from AbbVie that targets dopamine receptors differently than older Parkinson's medications. In the Phase 3 TEMPO trials, people w...
April 2, 2026
Fox Trial Finder is a free online tool that helps people with Parkinson's find clinical studies looking for participants. Instead of spending hours searching th...
April 1, 2026
The Parkinson's Foundation opened enrollment for a global registry tracking people with rarer Parkinson's subtypes, including LRRK2 genetic mutations and early-...
March 31, 2026
Fox Trial Finder, the online matching tool from the Michael J. Fox Foundation, connected over 15,000 people with Parkinson's to recruiting clinical trials last ...
AI Against Parkinson's